Written by Julia Rostova
ScanSource ended fiscal 2026 with the kind of quarter investors want from a technology distributor: double-digit sales growth, faster earnings growth, healthy cash generation and an outlook that remains constructive even before its proposed MicroAge acquisition. The result supports management’s argument that the company is evolving from a hardware-led distributor into a broader provider of recurring technology, connectivity and managed-services solutions. The pending transaction is the strategic test. It can improve margins and deepen customer relationships, but it also introduces integration risk and a meaningful cash outlay just as the core business is benefiting from a demand recovery.
The company’s fourth-quarter release reported net sales of $953.1 million for the quarter ended June 30, up 17.3% year on year. Sales increased 16.2% on the company’s non-GAAP organic, constant-currency basis, suggesting that the acceleration was not simply an acquisition or currency effect. Products and services revenue increased 17.4%, while recurring revenue rose 13.5% including acquisitions.
The Specialty Technology Solutions segment produced most of the gain. Its quarterly sales increased 17.6% to $927.2 million, supported by broad-based North American demand. Intelisys & Advisory sales grew 7.2% to $25.9 million, primarily from higher Resourcive sales. That contrast is useful: hardware and complex technology distribution drove the immediate surge, but ScanSource’s long-term quality of earnings will depend increasingly on its ability to grow recurring and advisory revenue faster than its more cyclical transaction-based activity.
Profitability was solid, although not uniformly stronger. Quarterly gross profit increased 14.0% to $119.8 million, but gross margin slipped 35 basis points to 12.6%. This is not necessarily a warning sign in a high-volume distributor; sales mix can move margin modestly from quarter to quarter. Still, it explains why investors should focus on operating leverage and free cash flow rather than assume that higher revenue automatically translates into expanding gross margins.
The company delivered that operating leverage below gross profit. GAAP operating income increased 18.5% to $31.7 million, GAAP net income rose 27.5% to $25.6 million and GAAP diluted EPS grew 40.9% to $1.24. On a non-GAAP basis, diluted EPS rose 43.1% to $1.46 and adjusted EBITDA increased 19.4% to $46.1 million. The reported GAAP improvement confirms that the underlying quarter was stronger, even though non-GAAP results exclude acquisition and divestiture costs, restructuring items, amortization of acquired intangibles and other adjustments.
For the full fiscal year, net sales increased 6.1% to $3.23 billion and GAAP EPS grew 21.3% to $3.64. Free cash flow was $113.8 million, while the company repurchased $97.9 million of stock. ScanSource ended June with $88.4 million of cash and $101.4 million of total debt, a manageable position before considering the proposed all-cash acquisition of MicroAge.
MicroAge is the strategic pivot. ScanSource has agreed to acquire the IT solutions integrator, managed-services provider and digital-transformation partner for $220.5 million in cash. MicroAge serves roughly 2,400 U.S. clients and employs more than 200 people. The purchase is expected to expand ScanSource’s capabilities in cloud, cybersecurity, data center and AI, while adding services that should be less exposed to pure hardware-cycle volatility. The transaction is expected to close in the September quarter, subject to customary approvals.
The opportunity is real, but the acquisition should not be treated as free growth. Integrating a solutions provider into a distributor requires careful management of sales incentives, customer ownership, vendor relationships and service-delivery quality. The deal is also large relative to ScanSource’s cash balance, so investors should watch funding terms, purchase accounting, integration costs and whether the promised margin benefit emerges on schedule.
Management’s FY2027 outlook intentionally excludes MicroAge and related purchase-accounting impacts. It calls for sales growth of 6% to 10%, adjusted EBITDA of $158 million to $165 million and at least $85 million of free cash flow. That is a prudent baseline: it gives investors a view of the core business before any acquisition synergies are credited.
Verdict on ScanSource (SCSC): BUY. The core business finished strongly, recurring revenue is becoming more important and the MicroAge deal offers a credible route to higher-value technology services. Risks include integration, distribution-margin pressure and a slower-than-expected demand recovery.
Price Target: $60.00
Disclaimer: This article is for informational and educational purposes only, not financial advice. Do your own due diligence. Past performance does not equal future results.
